Just a moment, the page is loading...

GSK-107072




A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants.
Rotavirus Vaccine
107072
NCT00329745
Infections, Rotavirus
Phase 3
The results of this study 107072 are summarised with studies 444563/028, 444563/029, 444563/030, 107070, and 107076 on the GSK Study Register. An annotated case report form is not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number is not available for this study because the study is not in scope of regulatory requirements to register studies.
January 2014